-
ATG4B Nuclear Translocation Links Energy Deficiency to DNA R
2026-04-25
This study identifies a metabolic-genomic axis in acute myeloid leukemia (AML) where energy deficiency induces nuclear translocation of ATG4B, inhibiting PRMT1-mediated DNA repair and accelerating leukemia progression. These findings refine our understanding of how metabolic stress drives genomic instability and reveal actionable targets for future research.
-
Isoliensinine Modulates TRPV1-AMPK to Counter MAFLD Fibrosis
2026-04-24
This study illuminates how isoliensinine from Plumula Nelumbinis attenuates hepatic fibrosis in metabolic associated fatty liver disease (MAFLD) by regulating lipid droplet metabolism in hepatic stellate cells (HSCs). The research identifies activation of the TRPV1-AMPK pathway as a pivotal mechanism, laying groundwork for advanced metabolic disease research and therapeutic strategies.
-
RBD-Targeted mRNA Outperforms Full Spike for MERS-CoV Vaccin
2026-04-24
The referenced study demonstrates that mRNA vaccines encoding the MERS-CoV receptor-binding domain (RBD) elicit stronger and more durable neutralizing antibody responses than those targeting the full spike protein, resulting in superior protection in a murine model. These findings inform rational vaccine design and underscore the value of epitranscriptomic optimization for next-generation RNA vaccines.
-
E-4031: hERG Potassium Channel Blocker for Cardiac Safety As
2026-04-23
E-4031 delivers nanomolar-selective hERG channel blockade for robust modeling of proarrhythmic substrates, QT interval prolongation, and TdP induction. APExBIO’s validated supply and detailed workflow guidance enable reproducible outcomes in advanced cardiac electrophysiology research.
-
P2RX1 Drives Mitochondrial Apoptosis in Ph+ ALL via CaMKII/P
2026-04-23
Li et al. (2025) identify P2RX1 as a critical regulator of mitochondrial apoptosis in Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). By elucidating a calcium/CaMKII-mediated inhibition of the PI3K/Akt pathway, their work highlights P2RX1’s potential as a therapeutic target and provides mechanistic insight into apoptosis modulation in drug-resistant leukemia.
-
GKT137831: Expanding Dual Nox1/Nox4 Inhibition for Oxidative
2026-04-22
Explore how GKT137831, a dual NADPH oxidase Nox1/Nox4 inhibitor, empowers researchers to dissect oxidative stress pathways with unprecedented specificity. This article uniquely bridges quantitative inhibition dynamics with recent membrane biology insights, informing advanced assay design.
-
Scalable EPSC-MSC EV Production for Regenerative Therapeutic
2026-04-22
Gong et al. established a robust, scalable biomanufacturing platform for producing extracellular vesicles (EVs) from induced mesenchymal stem cells (iMSCs) derived from extended pluripotent stem cells (EPSCs). This work addresses critical bottlenecks in EV production, offering standardized, high-yield EVs with therapeutic efficacy in pulmonary fibrosis models, and paves the way for clinical-grade regenerative medicine applications.
-
Aumolertinib Plus Radiation in EGFR-Mutant NSCLC Brain Metas
2026-04-21
This study systematically evaluates the therapeutic synergy of the third-generation EGFR-TKI aumolertinib combined with ionizing radiation in EGFR-mutant non-small cell lung cancer (NSCLC) brain metastases. Using in vivo and in vitro models, the authors provide robust evidence for enhanced antitumor efficacy, offering a promising strategy for overcoming the blood-brain barrier and improving patient outcomes.
-
25-Hydroxycholesterol, AMPK Activation, and TAM Immunometabo
2026-04-21
Xiao et al. (2024) uncovered how 25-hydroxycholesterol accumulation in tumor-associated macrophages (TAMs) activates lysosomal AMPK via a GPR155-mTORC1 complex, driving metabolic reprogramming and immunosuppression. Targeting the CH25H-25HC axis disrupts this pathway, enhancing anti-tumor immunity and response to anti-PD-1 therapy.
-
Asymmetric Synthesis of Axially Chiral Biaryls for Antimitot
2026-04-20
This article analyzes the pioneering asymmetric Suzuki cross-coupling method for preparing axially chiral biaryls, exemplified by analogues of (-)-rhazinilam with unique antimitotic properties. The research demonstrates the first application of atropo-enantioselective catalysis to a biologically significant target, providing insights for designing biaryl-based inhibitors relevant to cellular metabolism and cytoskeletal studies.
-
Vidarabine Monohydrate: Applied Protocols for Antiviral Rese
2026-04-20
Vidarabine monohydrate (Spongoadenosine monohydrate) stands out as a high-purity, DMSO-soluble nucleoside analog for efficient DNA replication interference in advanced virology workflows. This guide delivers stepwise protocols, troubleshooting insights, and actionable tips for maximizing reproducibility and sensitivity in inhibition of viral DNA synthesis assays.
-
Ceapin-A7: Selective ER Stress Blocker for Reliable ATF6α In
2026-04-19
Ceapin-A7 enables precise dissection of the ATF6α pathway, advancing endoplasmic reticulum stress research with reproducible, selective pathway inhibition. Its robust performance and workflow adaptability make it indispensable for unraveling the unfolded protein response in complex disease models.
-
E-4031: Advanced hERG Potassium Channel Blocker for Cardiac
2026-04-18
E-4031 stands as the benchmark hERG potassium channel blocker for modeling proarrhythmic risk and QT interval prolongation in cardiac electrophysiology research. This article details experimental workflows, assay optimization, and troubleshooting tips, drawing on both primary literature and practical lab scenarios for robust, reproducible results.
-
Advances in Hereditary Angioedema Therapy: Mechanistic and C
2026-04-17
This review by Caballero et al. critically evaluates the evolving landscape of hereditary angioedema (HAE) treatment, highlighting the mechanistic shift toward targeting the kallikrein-kinin system and the integration of new and repurposed drugs. The paper delineates the strategic pillars of acute attack management, short-term prophylaxis, and long-term prevention, while emphasizing the translational importance of recent pharmacological innovations for rare disease care.
-
Ceapin-A7: Selective ER Stress Blocker for Advanced UPR Rese
2026-04-16
Ceapin-A7 empowers cell biologists to precisely dissect the ATF6α pathway, offering reproducible control over ER stress signaling. Its high selectivity and robust workflow integration set a new benchmark for unfolded protein response (UPR) modulation in disease modeling and translational assays.